One minus distant disease-free survival (DDFS) stratified by PARs in ER-positive and ER-negative subgroups.

<p>Prognosis in relation to PAR-1 and PAR-2 status in patients with (a) ER-positive and (b) ER-negative tumors.</p

Univariable Cox regression analysis of factors for survival within 5 (DDFS) and 10 (BCM) years.

<p>*2-df likelihood ratio test.</p><p>Univariable Cox regression analysis of factors for survival within 5 (DDFS) and 10 (BCM) years.</p

Prognosis after CBC in relation to AIB1-status of BC2.

<p>Prognosis after CBC in relation to AIB1-status of BC2.</p

Patient and breast tumor characteristics in 221 premenopausal patients with lymph-node negative breast cancer.

<p>Patient and breast tumor characteristics in 221 premenopausal patients with lymph-node negative breast cancer.</p

Univariable Cox regression analysis of PAR-1 and PAR-2 for survival in relation to other variables.

<p>*Number of failures below 10.</p><p>Univariable Cox regression analysis of PAR-1 and PAR-2 for survival in relation to other variables.</p

Associations between other prognostic factors and PAR-1 and PAR-2, respectively.

<p>*Chi2-test; the trend version for histological grade.</p><p>Associations between other prognostic factors and PAR-1 and PAR-2, respectively.</p

Flow-chart of inclusion <i>vs</i>. exclusion in the study cohort.

<p>In analysis 36 patients with a local/regional recurrence of BC1 before diagnosis of BC2 were excluded in order not to confuse the results by eventual treatment given for the recurrence. We also excluded 3 patients with ambiguous distant metastasis-status and 1 patient with BC2 diagnosed at autopsy. Abbreviations: AIB1 <i>Amplified in breast cancer 1</i>, BC1 f<i>irst breast cancer</i>, BC2 <i>second breast cancer</i>, TMA <i>tissue microarray</i></p

Patient and tumor characteristics in relation to AIB1.

<p>Patient and tumor characteristics in relation to AIB1.</p

One minus distant disease-free survival (DDFS) stratified by PARs.

<p>Prognosis in relation to PAR-2 (a) and PAR-1 (b) status in the entire cohort.</p

One minus distant disease-free survival (DDFS) stratified by ER in PAR-2 and PAR-1 sub-groups.

<p>Prognosis in relation to PAR-2 (a) and PAR-1 (b) status in patients with ER-positive and ER-negative tumors.</p